Cover Image

Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xinyu Han, Xin Zhang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Haili Wang, Yu Gu, Tiejun Zhang
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Journal of Diabetes
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Non‐linear relationship between liver fibrosis and femoral neck bone mineral density in metabolic dysfunction‐associated fatty liver disease patients with type 2 diabetes mellitus
by: Jie Tao, et al.
Published: (2025)

Baseline and change in serum uric acid level over time and resolution of nonalcoholic fatty liver disease in young adults: The Kangbuk Samsung Health Study
by: Yoosun Cho, et al.
Published: (2024)

Spatiotemporal burden, risk factors, and genetic causality of non‐alcoholic fatty liver disease and type 2 diabetes mellitus comorbidity in Europe: A multi‐database analysis
by: Haoyang Hu, et al.
Published: (2025)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
by: Iskandar Idris
Published: (2024)

High estradiol/testosterone ratio increased the risk of metabolic dysfunction‐associated steatotic liver disease in men with type 2 diabetes mellitus
by: Meng‐Han Li, et al.
Published: (2025)

Association of physical activity and sports participation with insulin resistance and non‐alcoholic fatty liver disease in people with type 1 diabetes
by: M. de Vries, et al.
Published: (2024)

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
by: Michelle D. Lundholm, et al.
Published: (2024)

Elevated small dense low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio is associated with an increased risk of metabolic dysfunction associated fatty liver disease in Chinese patients with type 2 diabetes mellitus
by: Shouxing Yang, et al.
Published: (2024)

Diosgenin ameliorating non‐alcoholic fatty liver disease via Nrf2 ‐mediated regulation of oxidative stress and ferroptosis
by: Xin Zhang, et al.
Published: (2024)

Efficacy and safety of liraglutide in non‐alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta‐analysis
by: Weihan Kong, et al.
Published: (2025)

Risk factors and prediction score for new‐onset diabetes mellitus after liver transplantation
by: Ruiping Bai, et al.
Published: (2024)

Copper homeostasis and cuproptosis‐related genes: Therapeutic perspectives in non‐alcoholic fatty liver disease
by: Wangjing Tan, et al.
Published: (2024)

Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
by: Lijun Zhao, et al.
Published: (2024)

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
by: Mitsuhiro Shikamura, et al.
Published: (2024)

Reduced insulin clearance in paediatric metabolic (dysfunction)‐associated fatty liver disease and its dual role in beta‐cell offload and diabetes risk
by: Li Jiang, et al.
Published: (2024)

A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients
by: Tingting Li, et al.
Published: (2025)

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
by: Jae Hyun Bae, et al.
Published: (2024)

Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study
by: Hai‐Yang Yuan, et al.
Published: (2024)

Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
by: Yiming Wu, et al.
Published: (2025)

Diagnostic accuracy of Agile‐4 score for liver cirrhosis in patients with metabolic dysfunction‐associated steatotic liver disease. A systematic review and meta‐analysis of diagnostic test accuracy studies
by: Konstantinos Malandris, et al.
Published: (2024)

Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
by: Chloë Aernouts, et al.
Published: (2024)

Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes
by: Ebaa Al‐Ozairi, et al.
Published: (2024)

Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China‐PAR project
by: Yang Zhao, et al.
Published: (2024)

Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–2019
by: Naomi Holman, et al.
Published: (2025)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
by: Claudio Maffeis, et al.
Published: (2024)

Trajectories of body mass index and diabetes mellitus risk among elderly Chinese adults: A 10‐year longitudinal study
by: Yan Guo, et al.
Published: (2025)

Two‐tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross‐sectional study
by: Alessandro Mantovani, et al.
Published: (2025)

Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J‐mono post hoc analysis
by: Masato Yoneda, et al.
Published: (2025)

Correlation between time in range and mild cognitive impairment in older adults with type 2 diabetes mellitus
by: Jiajun Bao, et al.
Published: (2025)

The Ligustrum lucidum‐derived glycoside specnuezhenide alleviates metabolic‐associated fatty liver disease in mice via modulation of gut microbiota and the PPARα signalling pathway
by: Kai Gao, et al.
Published: (2026)

A trauma‐informed approach to type 1 diabetes mellitus in adults
by: Hadassah Buechner, et al.
Published: (2025)

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
by: Zhuolin Zhou, et al.
Published: (2025)

The relationship between folic acid and nonalcoholic fatty liver disease
by: Bing'er Xu, et al.
Published: (2024)

High‐intensity interval training induces lactate dehydrogenase B lactylation to inhibit hepatic lipogenesis to alleviate metabolic dysfunction‐associated fatty liver disease
by: Wenhua Huang, et al.
Published: (2026)

Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study
by: Nora Hennies, et al.
Published: (2024)

Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population. A probabilistic survey
by: Salvador Villalpando
Published: (2010)

Application of construction and validation of logistic regression model in risk prediction of non‐proliferative diabetic retinopathy in type 2 diabetes mellitus
by: Jiaoyan Zhang, et al.
Published: (2026)

Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes
by: Ebaa Al Ozairi, et al.
Published: (2025)

Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes
by: Hiroyuki Ito, et al.
Published: (2025)

Impact of bariatric surgery on glycaemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: A meta‐analysis
by: Xu Han, et al.
Published: (2025)